(Reuters) - Johnson & Johnson reported a 4.5 percent rise in quarterly profit on Tuesday and boosted its sales and earnings per share guidance, as rising sales of its cancer drugs Zytiga and Darzalex helped offset falling sales of blockbuster arthritis drug Remicade.

The healthcare conglomerate's net earnings rose to $3.93 billion, or $1.44 per share, in the third quarter, from $3.76 billion, or $1.37 per share, a year earlier.

Sales rose 3.6 percent to $20.35 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)